Mapping the agonist-binding site of GABAB type 1 subunit sheds light on the activation process of GABAB receptors

被引:103
作者
Galvez, T
Prézeau, L
Milioti, G
Franek, M
Joly, C
Froestl, W
Bettler, B
Bertrand, HO
Blahos, J
Pin, JP
机构
[1] CNRS, UPR9023, CCIPE, F-34094 Montpellier 5, France
[2] Charles Univ, Lab Mol Physiol, Med Sch 3, Prague 2, Czech Republic
[3] Acad Sci Czech Republ, Prague 2, Czech Republic
[4] Novartis Pharma AG, TA Nervous Syst, CH-4002 Basel, Switzerland
[5] Mol Simulat Inc, F-91893 Orsay, France
关键词
D O I
10.1074/jbc.M007848200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The gamma -amino-n-butyric acid type B (GABA(B)) receptor is composed of two subunits, GABA(B)1 and GABA(B)2, belonging to the family 3 heptahelix receptors. These proteins possess two domains, a seven transmembrane core and an extracellular domain containing the agonist binding site. This binding domain is likely to fold like bacterial periplasmic binding proteins that are constituted of two lobes that close upon ligand binding. Here, using molecular modeling and site-directed mutagenesis, we have identified residues in the GABA(B)1 subunit that are critical for agonist binding and activation of the heteromeric receptor. Our data suggest that two residues (Ser(246) and Asp(471)) located within lobe I form H bonds and a salt bridge with carboxylic and amino groups of GABA, respectively, demonstrating the pivotal role of lobe I in agonist binding. Interestingly, our data also suggest that a residue within lobe II (Tyr(366)) interacts with the agonists in a closed form model of the binding domain, and its mutation into Ala converts the agonist baclofen into an antagonist. These data demonstrate the pivotal role played by the GABA(B)1 subunit in the activation of the heteromeric GABA(B) receptor and are-consistent with the idea that a closed state of the binding domain of family 3 receptors is required for their activation.
引用
收藏
页码:41166 / 41174
页数:9
相关论文
共 45 条
[1]   Structure of a glutamate-receptor ligand-binding core in complex with kainate [J].
Armstrong, N ;
Sun, Y ;
Chen, GQ ;
Gouaux, E .
NATURE, 1998, 395 (6705) :913-917
[2]   Intermolecular interactions between dimeric calcium-sensing receptor monomers are important for its normal function [J].
Bai, M ;
Trivedi, S ;
Kifor, O ;
Quinn, SJ ;
Brown, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :2834-2839
[3]   Molecular tinkering of G protein-coupled receptors: an evolutionary success [J].
Bockaert, J ;
Pin, JP .
EMBO JOURNAL, 1999, 18 (07) :1723-1729
[4]   The agonist-binding domain of the calcium-sensing receptor is located at the amino-terminal domain [J].
Bräuner-Osborne, H ;
Jensen, AA ;
Sheppard, PO ;
O'Hara, P ;
Krogsgaard-Larsen, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (26) :18382-18386
[5]   CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID [J].
BROWN, EM ;
GAMBA, G ;
RICCARDI, D ;
LOMBARDI, M ;
BUTTERS, R ;
KIFOR, O ;
SUN, A ;
HEDIGER, MA ;
LYTTON, J ;
HEBERT, SC .
NATURE, 1993, 366 (6455) :575-580
[6]   SUBSTITUTION OF 3 AMINO-ACIDS SWITCHES RECEPTOR SPECIFICITY OF G(Q)ALPHA TO THAT OF G(I)ALPHA [J].
CONKLIN, BR ;
FARFEL, Z ;
LUSTIG, KD ;
JULIUS, D ;
BOURNE, HR .
NATURE, 1993, 363 (6426) :274-276
[7]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[8]   Homology modeling of metabotropic glutamate receptors. (mGluRs) structural motifs affecting binding modes and pharmacological profile of mGluR1 agonists and competitive antagonists [J].
Costantino, G ;
Pellicciari, R .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (20) :3998-4006
[9]   Intracellular retention of recombinant GABAB receptors [J].
Couve, A ;
Filippov, AK ;
Connolly, CN ;
Bettler, B ;
Brown, DA ;
Moss, SJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (41) :26361-26367
[10]   The heteromeric GABA-B receptor recognizes G-protein α subunit C-termini [J].
Franek, M ;
Pagano, A ;
Kaupmann, K ;
Bettler, B ;
Pin, JP ;
Blahos, J .
NEUROPHARMACOLOGY, 1999, 38 (11) :1657-1666